After Merck's cough drama, GSK knew what to do with Bellus asset
Nov 30, 2023 · By the time GSK sealed the deal on Bellus Health in April, the U.K. pharma knew exactly what not to do with the phase 3 chronic cough program. The company had watched Merck & Co. struggle with...
GSK reaches agreement to acquire late-stage biopharmaceutical …
Apr 18, 2023 · GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash ...
GSK completes acquisition of BELLUS Health
Jun 28, 2023 · It is estimated that 28 million patients suffer from chronic cough, with 10 million patients globally and 6 million in the United States (US) and European Union (EU) suffering from RCC for over a year. 1 RCC is defined as a persistent cough for more than eight weeks that does not respond to treatment for an underlying condition or is otherwise ...
GSK Inks $2 Billion For Cough Medicine Biotech To Bolster Drug ... - Forbes
Apr 18, 2023 · Pharma giant GlaxoSmithKline on Tuesday announced a deal to buy Canadian biotech Bellus Health for $2 billion, betting big on the firm’s cough medicine as it moves to shore up its slender drug ...
GSK to buy Bellus Health and its chronic cough drug for $2B
Apr 18, 2023 · GSK on Tuesday said it will pay $2 billion to acquire Bellus Health, a Canada-based developer of an experimental drug for chronic cough that’s in late-stage clinical trials. Deal terms value each Bellus share at $14.75, roughly double their closing price on Monday.
GSK inks $2B Bellus buyout to challenge Merck for cough market
Apr 18, 2023 · Merck & Co. has a new challenger for the chronic cough market: GSK. The British Big Pharma is set to pay $2 billion to buy Bellus Health, securing a late-phase rival to Merck’s stuttering...
Camlipixant by GSK for Chronic Cough: Likelihood of Approval
Jan 19, 2025 · Camlipixant (NEO-5937) is under development for the treatment of chronic refractory cough and and other cough hypersensitization-related disorders. The drug candidate is a benzoimidazole derivative, formulated as a tablet and is administered through oral route.
Respiratory, immunology and inflammation | GSK US
Refractory chronic cough. Approximately 28 million people suffer from chronic cough, with about 10 million worldwide suffering from refractory chronic cough (RCC). RCC is a cough that persists for more than eight weeks and doesn’t respond to treatment for an underlying condition or is otherwise unexplained.
GSK bets $2 bln on Bellus cough drug to soothe pipeline fears
Apr 18, 2023 · GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on respiratory therapies.
GSK bolsters respiratory pipeline with Bellus Health buy
6 days ago · GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough.
- Some results have been removed